Tech Company Financing Transactions
TransMolecular Funding Round
Easton Capital, Aperture Venture Partners and MDS Capital participated in a $33.2 million Series C venture round for TransMolecular. The funding round closed on 3/1/2004.
Transaction Overview
Company Name
Announced On
3/1/2004
Transaction Type
Venture Equity
Amount
$33,200,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from this financing will be used primarily to conduct multiple clinical studies of TransMolecular's anti-cancer compounds, and advance the pre-clinical development of drug candidates for a number of indications.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
840 Memorial Drive Second Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
TransMolecular, Inc. is a therapeutics biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat human diseases having inadequate pharmaceutical alternatives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Radie
Vice President
Douglas Jacoby
Vice President
Alison O'Neill
VP - Finance
Jonathan Jones
VP - Manufacturing
Abdellah Sentissi
VP - Operations
Amy Bock
VP - Regulatory Affairs
Susan Stewart
Browse more venture capital transactions:
Prev: 3/1/2004: LogLogic venture capital transaction
Next: 3/1/2004: Actiance venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs